Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for the prevention and treatment of COVID-19. Its lead product, PEMGARDA (pemivibart), received FDA Emergency Use Authorization in March 2024 for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients. Its next-generation candidate, VYD2311, is being developed for broader COVID-19 prevention under a BLA pathway, leveraging the company's REVOLUTION clinical program.
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092547 | EDGAR | 127K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042332 | EDGAR | 123K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037610 | EDGAR | 120K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009516 | EDGAR | 121K words |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005112 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-349215 | EDGAR | 35K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268076 | EDGAR | 35K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-109029 | EDGAR | 33K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071974 | EDGAR | 29K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126735 | EDGAR | 35K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096674 | EDGAR | 33K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057017 | EDGAR | 27K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062043 | EDGAR | 33K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041352 | EDGAR | 32K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021235 | EDGAR | 28K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024516 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017242 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-29 | 0001193125-26-406007 | EDGAR | — |
| 2026-09-01 | 0001193125-26-377493 | EDGAR | 2K words |
| 2026-08-13 | 0001193125-26-349193 | EDGAR | 4K words |
| 2026-07-24 | 0001193125-26-316066 | EDGAR | 1K words |
| 2026-03-05 | 0001193125-26-092528 | EDGAR | 5K words |
| 2026-01-08 | 0001193125-26-006997 | EDGAR | 3K words |
| 2025-12-23 | 0001193125-25-329488 | EDGAR | 1K words |
| 2025-11-24 | 0001193125-25-291992 | EDGAR | 1K words |
| 2025-11-19 | 0001193125-25-288347 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-268057 | EDGAR | 5K words |
134 total filings indexed. 107 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001832038 |
| Ticker | IVVD |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.invivyd.com |
| Listed | 2021-08-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IVVD (~200 tokens, structured JSON with cryptographic provenance)